Table 2.
Univariate analysis of risk factors associated with OS and PFS
| Variables | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (> 60 vs. ≤ 60) | 1.80 (0.98–3.81) | 0.065 | 1.04 (0.52–2.30) | 0.205 |
| Gender (male vs. female) | 1.45 (1.07–1.92) | 0.052 | 0.29 (0.13–0.86) | 0.905 |
| B symptoms (yes vs. no) | 0.68 (0.24–1.63) | 0.024 | 0.35 (0.12–1.98) | 0.032 |
| Lugano stage (I–II2 vs. III–IV) | 2.28 (1.28–4.14) | 0.001 | 1.52 (0.65–3.58) | 0.018 |
| LDH (elevated vs. normal) | 1.31 (1.04–1.67) | 0.015 | 0.67 (0.33–1.42) | 0.327 |
| Local tumor invasiveness (yes vs. no) | 0.46 (0.22–0.96) | 0.024 | 0.32 (0.15–0.66) | 0.037 |
| Treatment (chemotherapy or radiotherapy vs. both) | 0.67 (0.33–1.42) | 0.004 | 0.35 (0.12–2.30) | 0.041 |
| Absolute lymphocyte count (≤ 1.5 × 109/L vs. > 1.5 × 109/L) | 1.56 (0.72–3.40) | 0.002 | 1.24 (0.62–2.08) | 0.006 |
| Absolute monocyte count (≤ 0.5 × 109/L vs. > 0.5 × 109/L) | 0.53 (0.21–1.37) | 0.102 | 0.45 (0.13–2.49) | 0.361 |
| LMR (≤ 2.7 vs. > 2.7) | 4.21 (1.53–11.56) | 0.000 | 2.78 (1.15–6.76) | 0.034 |